A traditional Mediterranean diet with one serving of mixed nuts can reverse metabolic syndrome.
A traditional Mediterranean diet supplemented with one serving per day of mixed nuts can reverse the metabolic syndrome, a constellation of symptoms known to increase the risk for cardiovascular disease (CVD), diabetes mellitus, and mortality.
The finding comes from a multicenter 1-year randomized trial called PREDIMED (Prevención Dieta Mediterránea). Over 1,200 adults at high risk for CVD received quarterly education about a Mediterranean diet, which consists of a high intake of cereals, vegetables, and fruits; a moderate intake of fish and alcohol (mostly wine); and a low intake of dairy, meats, and sweets. This diet was supplemented with either 1 L/wk of virgin olive oil or 30 g/d of mixed nuts.
At 1 year, prevalence of the metabolic syndrome was reduced by 6.7% in the group following the Mediterranean diet supplemented with olive oil, by 13.7% in the group following the Mediterranean diet supplemented with nuts, and by 2.0% in the control group. After adjusting for various factors, the odds ratio for reversing the metabolic syndrome was 1.3 in the Mediterranean diet plus olive oil group and 1.7 in the Mediterranean diet plus nuts group, compared with the control group.
Salas-Salvadó Fernández-Ballart J, Ros E, et al. Effect of a Mediterranean diet supplemented with nuts on metabolic syndrome status. Arch Intern Med. 2008;168:2449-2458.
Increase in ED visits for hypertensive disorders from 2006 to 2020 reported
September 18th 2024In a recent study, reported rates on emergency department utilization for hypertensive disorders of pregnancy and the postpartum period were higher in 2020 than 2006, with rates especially high among non-Hispanic Black, Hispanic, and Asian patients.
Read More
SKYLIGHT trials confirm safety and efficacy of fezolinetant against sleep disturbances
September 13th 2024At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.
Read More